Why the investor craze for Ozempic and rival weight-loss drugs may resume next year

Why the investor craze for Ozempic and rival weight-loss drugs may resume next year



Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts said


Source link

Check Also

Wall Street’s Santa Claus rally window is about to open with the Dow down in December

Wall Street’s Santa Claus rally window is about to open with the Dow down in December

Stocks have struggled ahead of the holidays despite Friday’s rally. Source link

Leave a Reply

Your email address will not be published. Required fields are marked *